301 related articles for article (PubMed ID: 33797839)
1. ISG15 is downregulated by KLF12 and implicated in maintenance of cancer stem cell-like features in cisplatin-resistant ovarian cancer.
Zhang Q; Wang J; Qiao H; Huyan L; Liu B; Li C; Jiang J; Zhao F; Wang H; Yan J
J Cell Mol Med; 2021 May; 25(9):4395-4407. PubMed ID: 33797839
[TBL] [Abstract][Full Text] [Related]
2. ISG15 suppresses translation of ABCC2 via ISGylation of hnRNPA2B1 and enhances drug sensitivity in cisplatin resistant ovarian cancer cells.
Wang JM; Liu BQ; Zhang Q; Hao L; Li C; Yan J; Zhao FY; Qiao HY; Jiang JY; Wang HQ
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118647. PubMed ID: 31926942
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
4. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells.
Choi EJ; Seo EJ; Kim DK; Lee SI; Kwon YW; Jang IH; Kim KH; Suh DS; Kim JH
Oncotarget; 2016 Jan; 7(3):3506-19. PubMed ID: 26654944
[TBL] [Abstract][Full Text] [Related]
5. Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis.
Wang Y; Zhao G; Condello S; Huang H; Cardenas H; Tanner EJ; Wei J; Ji Y; Li J; Tan Y; Davuluri RV; Peter ME; Cheng JX; Matei D
Cancer Res; 2021 Jan; 81(2):384-399. PubMed ID: 33172933
[TBL] [Abstract][Full Text] [Related]
6. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
[TBL] [Abstract][Full Text] [Related]
7. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
8. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis.
Mak CS; Yung MM; Hui LM; Leung LL; Liang R; Chen K; Liu SS; Qin Y; Leung TH; Lee KF; Chan KK; Ngan HY; Chan DW
Mol Cancer; 2017 Jan; 16(1):11. PubMed ID: 28095864
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
10. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells.
Hao L; Wang JM; Liu BQ; Yan J; Li C; Jiang JY; Zhao FY; Qiao HY; Wang HQ
Biochim Biophys Acta Mol Cell Res; 2021 Jan; 1868(1):118878. PubMed ID: 33011193
[TBL] [Abstract][Full Text] [Related]
11. Proto-oncogene c-Myb potentiates cisplatin resistance of ovarian cancer cells by downregulating lncRNA NKILA and modulating cancer stemness and LIN28A-let7 axis.
Zhang XY; Zhu BC; He M; Dong SS
J Ovarian Res; 2024 May; 17(1):102. PubMed ID: 38745302
[TBL] [Abstract][Full Text] [Related]
12. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
13. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin induces stemness in ovarian cancer.
Wiechert A; Saygin C; Thiagarajan PS; Rao VS; Hale JS; Gupta N; Hitomi M; Nagaraj AB; DiFeo A; Lathia JD; Reizes O
Oncotarget; 2016 May; 7(21):30511-22. PubMed ID: 27105520
[TBL] [Abstract][Full Text] [Related]
15. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
16. HO-3867, a curcumin analog, sensitizes cisplatin-resistant ovarian carcinoma, leading to therapeutic synergy through STAT3 inhibition.
Selvendiran K; Ahmed S; Dayton A; Kuppusamy ML; Rivera BK; Kálai T; Hideg K; Kuppusamy P
Cancer Biol Ther; 2011 Nov; 12(9):837-45. PubMed ID: 21885917
[TBL] [Abstract][Full Text] [Related]
17. Lumiflavin increases the sensitivity of ovarian cancer stem-like cells to cisplatin by interfering with riboflavin.
Yang R; Wei Z; Wu S
J Cell Mol Med; 2019 Aug; 23(8):5329-5339. PubMed ID: 31187586
[TBL] [Abstract][Full Text] [Related]
18. CD10
Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
20. ISG15 predicts poor prognosis and promotes cancer stem cell phenotype in nasopharyngeal carcinoma.
Chen RH; Du Y; Han P; Wang HB; Liang FY; Feng GK; Zhou AJ; Cai MY; Zhong Q; Zeng MS; Huang XM
Oncotarget; 2016 Mar; 7(13):16910-22. PubMed ID: 26919245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
